Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Phase 1
- Conditions
- Lymphoma, Non-HodgkinLymphoma, T-Cell
- Interventions
- Biological: Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 71
- Registration Number
- NCT05557903
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Najing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)
Phase 3
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2018-01-03
- Target Recruit Count
- 216
- Registration Number
- NCT02786407
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
Phase 1
- Conditions
- Meningococcal Meningitis
- Interventions
- Biological: freeze-dried group ACYW135 MCV
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2015-06-25
- Target Recruit Count
- 200
- Registration Number
- NCT02481232
- Locations
- 🇨🇳
Hubei CDC, Wuhan, Hubei, China
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
Phase 3
- Conditions
- Chronic Migraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2018-01-03
- Target Recruit Count
- 288
- Registration Number
- NCT02291380
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
Phase 3
Completed
- Conditions
- Cerebrovascular Accident
- Interventions
- Drug: placebo
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2016-09-26
- Target Recruit Count
- 180
- Registration Number
- NCT02280083
© Copyright 2025. All Rights Reserved by MedPath